CTA

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Retrieved on: 
Wednesday, March 13, 2024
Research, Neurology, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, STAC, AAV, Sangamo Therapeutics, Gene, Brain, Capsid, Gene expression, ALS, BBB, Central nervous system, Novartis, CNS, CTA, DRG, Traffic barrier, Prion, NHP, Tropism, IND, Nav1.7, Neuron, Biogen, Tauopathy, Excipient, Therapy, DSM-IV codes, Spinal cord, Liver, Animal, Vaccine

Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.

Key Points: 
  • Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.
  • In NHP studies when administered intravenously at clinically relevant doses, STAC-BBB demonstrated its potential to be a leading neurotropic capsid.
  • Exhibited 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published neurotropic capsid variants evaluated in the study.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.

Ai for Alpha Unveils Its Cutting Edge New CTA Daily Decoding Strategy: The "CTA Decoding 2.0."

Retrieved on: 
Tuesday, March 12, 2024
Professional Services, Data Analytics, Technology, Software, Finance, Fintech, Artificial Intelligence, CTA, Business development, Alpha, Jacquot, Machine learning, Tutoring

AI for Alpha , a leading fintech company specializing in machine learning for advanced investment solutions, announces the release of its CTA Decoding 2.0 Strategy.

Key Points: 
  • AI for Alpha , a leading fintech company specializing in machine learning for advanced investment solutions, announces the release of its CTA Decoding 2.0 Strategy.
  • "This cutting-edge strategy represents a significant leap forward in Ai for Alpha's decoding replication technology, offering a refined approach to the already high-performing CTA replication model developed by Ai for Alpha," says Beatrice Guez, CEO of Ai for Alpha.
  • "The CTA Decoding 2.0 has been designed in response to the success of our initial CTA decoding strategy launched in 2022," adds Thomas Jacquot, head of Business Development.
  • The CTA 2.0 strategy introduces two significant innovations over the original Ai for Alpha CTA Decoding:
    The enhanced CTA Decoding infers exposure to both Trend factors and individual markets across various asset classes.

CES Audit Confirms Decision Makers Flocked to 2024 Show

Retrieved on: 
Thursday, March 28, 2024
LAS, Consumer Technology Association, UFI, CES, CTA, Growth, Audit

LAS VEGAS, March 28, 2024 /PRNewswire/ -- The Consumer Technology Association (CTA)® announced its final attendance data for CES® 2024—the world's most powerful tech event—revealing 15% growth in the number of senior-level executives attending the show compared to the previous year. 138,739 participants from across the globe converged in Las Vegas to explore groundbreaking technologies across 40+ categories. A record 1442 companies exhibited on the show's startup floor, Eureka Park.

Key Points: 
  • CES 2024—the world's most powerful tech event—saw 15% growth of senior executives and 138,739 total global participants.
  • "Executives and business decision makers see the value in face-to-face meetings and access to global media, which only a show like CES can provide.
  • "We were thrilled not just to welcome more than 138,000 people to CES 2024, but to back up those numbers with an independent audit," said Kinsey Fabrizio, President, CTA.
  • CES 2025 will return to Las Vegas from January 7-10, 2025, promising another groundbreaking showcase of innovation and collaboration.

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

Retrieved on: 
Thursday, March 28, 2024
Agreement, Transplant, CASI Pharmaceuticals, CASI, Patient, Travel, PTCL, Immunoglobulin G, CMC, Depreciation, Bone marrow, Therapy, VCP, Marketing, Research, Cleave, Pralatrexate, MCL, Rituximab, AML, Pembrolizumab, Trial of the century, Myelodysplastic syndrome, Melphalan, MDS, Clinical trial, Follicular lymphoma, Republic, Multiple myeloma, Acute myeloid leukemia, Annual report, National Medical Products Administration, Haematopoietic system, FDA, Cayman, CD19, NMPA, COVID-19, CTA, HKIAC, NHL, Non-Hodgkin lymphoma, MICL, Pharmaceutical industry

BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.

Key Points: 
  • BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.
  • CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA®, 33% lower than the same period in 2022.
  • 2023 marks a major milestone for CASI and our partner Juventas; Inaticabtagene Autoleucel (CNCT-19 CAR-T cell therapy) was approved by National Medical Products Administration (NMPA) in November 2023.
  • As of December 31, 2023, CASI had cash, cash equivalents and short term investment of $29.1 million compared to $48.6 million as of December 31, 2022.

CTA Construction Managers Celebrates Groundbreaking for Lincoln-Eliot Elementary School

Retrieved on: 
Tuesday, March 26, 2024
Project management, OPM, Honor Award, CTA, City, Aquinas College, Student, American Institute, Benjamin Franklin, Population growth, Ageing, Construction

NEWTON, Mass., March 26, 2024 /PRNewswire/ -- CTA Construction Managers, based in Waltham, MA was awarded the contract for the 94,000 square foot school campus in Newton. The contract includes renovation of an existing structure, once part of Aquinas College, and construction of a new addition.

Key Points: 
  • CTA Construction Managers was awarded the contract for the 94,000 square foot school campus in Newton, MA.
  • NEWTON, Mass., March 26, 2024 /PRNewswire/ -- CTA Construction Managers, based in Waltham, MA was awarded the contract for the 94,000 square foot school campus in Newton.
  • This will be the 47th large-scale school construction project CTA Construction Managers has built in Massachusetts.
  • CTA Construction Managers and Arrowstreet previously worked together on The Ben Franklin Classical Charter School, which won the prestigious Honor Award from the American Institute of Architects.

CTA Construction Managers Celebrates Topping Off of Concord Middle School

Retrieved on: 
Wednesday, March 20, 2024
Electricity, Heat, Steel, Superintendent, Lowell Elementary School, CTA, Foot, MEP, Student, Tutoring

CONCORD, Mass., March 20, 2024 /PRNewswire/ -- CTA Construction Managers, members of the community, school building committee members, and representatives from Hill-LiRo, SMMA, and Ewing Cole Architects were on hand to celebrate the "Topping Off" of the new Concord Middle School. CTA Construction Managers was awarded the contract to construct the new 142,537 square foot middle school in 2023.

Key Points: 
  • CONCORD, Mass., March 20, 2024 /PRNewswire/ -- CTA Construction Managers, members of the community, school building committee members, and representatives from Hill-LiRo, SMMA, and Ewing Cole Architects were on hand to celebrate the "Topping Off" of the new Concord Middle School.
  • CTA Construction Managers was awarded the contract to construct the new 142,537 square foot middle school in 2023.
  • The construction of the new school is adjacent to the existing Sanborn Middle School.
  • This will be the 46th large-scale school construction project CTA Construction Managers has built in Massachusetts.

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Wednesday, March 6, 2024
CONNECT, SAD, Research, Dystrophin, Clinical trial, Food, DMD, Common, DM1, Safety, Health care, Patient, MHRA, Disease, Three Months, Male, IND, Enrollment, PGN, U.K, MBNL1, CTA, Medication, Pharmaceutical industry

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and highlighted recent corporate developments.

Key Points: 
  • “With important data readouts expected from our two lead programs, 2024 has the potential to be a transformational year for PepGen.
  • People with myotonic dystrophy type 1 (DM1) currently have no approved treatment options that target the root cause of the disease.
  • Financial Results for the Three Months and Twelve Months ended December 31, 2023
    Cash and cash equivalents were $110.4 million as of December 31, 2023.
  • Net loss was $78.6 million for the year ended December 31, 2023, compared to $69.1 million for the same period in 2022.

GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom

Retrieved on: 
Monday, March 4, 2024
Oxygen, IPF, Idiopathic disease, Serum, Doctor of Philosophy, Blood, Homeostasis, Idiopathic pulmonary fibrosis, Inflammation, Vital signs, Safety, Health care, BAL, Biomarker, Pharmacokinetics, Patient, NKT, Natural killer T cell, Bronchoalveolar lavage, NIHR, Movement, GRI, CTA, Immune system, Pharmaceutical industry

LA JOLLA, CA, March 04, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the UK.

Key Points: 
  • The MHRA is the UK regulatory authority, a government agency, for medicines and medical devices.
  • The MHRA is responsible for the regulation of medicines and medical devices and equipment used in healthcare and the investigation of harmful incidents.
  • “We are pleased to receive authorization from the MHRA and take a step in the global expansion of our clinical development for GRI-0621.
  • We are focused on driving this program forward and generating important data readouts this year,” Marc Hertz, PhD, Chief Executive Officer of GRI Bio.

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
Monday, March 4, 2024
DMD, Duchenne muscular dystrophy, Safety, Health care, Patient, MHRA, CTA, Pharmaceutical industry

We believe this study, together with the data generated in our ongoing CONNECT1-EDO51 trial, could potentially support accelerated approval of EDO51, subject to alignment with regulators,” said James McArthur, Ph.D., President and CEO of PepGen.

Key Points: 
  • We believe this study, together with the data generated in our ongoing CONNECT1-EDO51 trial, could potentially support accelerated approval of EDO51, subject to alignment with regulators,” said James McArthur, Ph.D., President and CEO of PepGen.
  • Participants will receive seven doses of either PGN-EDO51 or placebo at approximately four-week intervals for 24 weeks.
  • Per the protocol, the starting dose will escalate from 5 mg/kg to 10 mg/kg, and potentially higher; the same dose levels are being evaluated in the ongoing CONNECT1-EDO51 trial.
  • Further dose escalation will be determined based on evaluation of safety data from prior dose cohort(s).

Prime Medicine Reports Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 1, 2024
Sequence, Composition, Liver, RHO, Immunotherapy, Investment, FDA, Research and development, HSC, Food, CGD, Patent, SCIP, Lung, Ataxia, Cystic Fibrosis Foundation, Hematology, Administration, Patient, Target, IND, AAV, CTA, Pharmaceutical industry

CAMBRIDGE, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2023 and provided a business update.

Key Points: 
  • “In 2024, we anticipate undergoing a significant transformation, maturing into a clinical-stage company and bringing the first-ever Prime Editing-based therapeutic candidate to patients.
  • This funding will allow Prime Medicine to progress two distinct strategies for applying Prime Editing to treat CF: hotspot editing and PASSIGE™ (Prime Assisted Site Specific Integrase Gene Editing).
  • Gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $161.0 million.
  • In January 2024, Prime Medicine announced the appointment of Allan Reine, M.D., as the Company’s Chief Financial Officer.